India & Natco Pharma
5 shared events · Importance 3 · Last updated Mar 31, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
India: India is a key battleground for weight-loss drugs due to its large obesity population and is experiencing significant competition between Novo Nordisk and Eli Lilly and Company.
Natco Pharma: Natco Pharma is one of the Indian generic drugmakers that will likely offer lower-priced versions of semaglutide once the patent expires.
Nov 11, 2025 · 6 articles
Business
India: Lupin (company) and Natco Pharma, both headquartered in India, have expanded their global reach through this U.S. FDA approval.
Natco Pharma: Natco Pharma, in alliance with Lupin (company), secured U.S. FDA approval for its Abbreviated New Drug Application for Eribulin Mesylate Injection, enhancing its oncology portfolio and market presence.
Jun 03, 2026 · 8 articles
Business
Natco Pharma: Natco Pharma is one of several Indian companies that launched generic versions of semaglutide, increasing competition for Novo Nordisk.
Mar 30, 2026 · 8 articles
Business
Natco Pharma: Natco Pharma is a key player in launching generic semaglutide in India at a significantly lower price, aiming to capture a substantial share of the weight-loss drug market.
Mar 20, 2026 · 8 articles
Business
Natco Pharma: Natco Pharma continues to be an investor in Pee Safe.
Mar 17, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how India and Natco Pharma interact across events, view sentiment trends, and discover connected entities.
Open Dashboard